Navigation Links
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selective VEGF signaling inhibitor - shows over a quarter of patients alive and progression- free at six months(1)

CHICAGO, June 04, 2007 /PRNewswire/ -- Data for the investigational agent cediranib (AZD2171) were presented today at the annual meeting of the American Society of Clinical Oncology (ASCO) from a study in patients with recurrent glioblastoma (GBM), an invasive form of brain tumor with a high unmet medical need. (1)

Cediranib Phase II monotherapy study in recurrent glioblastoma (GBM) Results from the National Cancer Institute (NCI) sponsored study at the Massachusetts General Hospital (MGH) Cancer Center, showed 8 patients (27.6%) of the 31 patients with recurrent glioblastoma treated with cediranib, were alive and progression-free at six months.(1) Recurrent glioblastoma is the most aggressive form of primary brain tumor. The dose limiting toxicities most commonly observed in this study included hypertension, fatigue, and diarrhea.

Cediranib is a selective VEGF signaling inhibitor that targets all three VEGF receptors.(2) VEGF signalling is a key driver of angiogenesis -- the formation of new blood vessels that tumors need to grow and spread. Cediranib is currently in Phase II/III development for advanced non-small cell lung cancer (NSCLC) and advanced colorectal cancer (CRC) -- as well as being investigated as part of a wide-ranging signal search program in other tumors such as glioblastoma.

Commenting on these results, Dr. Tracy Batchelor, MD, chief of Neuro- Oncology in the Massachusetts General Hospital (MGH) Cancer Center, Associate Professor of Neurology at Harvard Medical School and lead author of the Phase II study said, "These encouraging data showing effects on progression-free survival warrant further investigation to validate these initial trial results."

"In addition, cediranib alleviated brain swelling
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:6/19/2013)... June 19, 2013   NextDocs announced today ... clinical research organization, at DIA 2013 , the ... will present case studies that explore best practices for ... electronic trial master file (eTMF) systems. ... present alongside Krystyna Kowalczyk , executive vice president ...
(Date:6/19/2013)... CLARA, Calif. , June 19, 2013 /PRNewswire/ ... control solutions for life sciences process applications, announced ... glass bioreactors for upstream cell culture and fermentation.  ... a new product family of Finesse bioreactors and ... and cGMP applications.  They are fully compatible with ...
(Date:6/19/2013)... India , June 19, 2013 ... Bureau has recently added DrugPatentWatch to ... ( http://www.bharatbook.com/drugpatentwatch-tour.pdf )      ... provides comprehensive information on pharmaceutical, drug ... information supports the critical business functions ...
Breaking Medicine Technology:NextDocs and Novella to Present on eTMF at DIA 2013 2Finesse Solutions Launches Next Generation SmartGlass 3L Bioreactors for Cell Culture and Fermentation 2Drug Patent Watch 2Drug Patent Watch 3
... 13 Otix Global, Inc. (Otix) (Nasdaq: OTIX ... today announced that it has decided to discontinue its operations ... decision, Sam Westover, Chairman and CEO of Otix stated, "the ... stability of our business and, as a result, we have ...
... Applied Precision is sending its Mobile ... and research centers.   The Applied Precision ... 40-foot coach bus.  The lab is equipped with Applied ... a wet lab.  New this year is a special ...
Cached Medicine Technology:Otix Global, Inc. to Discontinue German Operations 2Otix Global, Inc. to Discontinue German Operations 3Applied Precision's Mobile Imaging Lab Hits the Road for a Cross-Country Journey 2
(Date:6/19/2013)... June 19, 2013 Today, Zane Benefits, ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution and ... Benefits’ website, as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:6/19/2013)... 19, 2013 The Journal of Parasitology ... today’s computer software, it creates questions of ethics. For ... As an already published case shows, scientific publications need ... The Journal of Parasitology features a ... a 2004 article published in the Journal of the ...
(Date:6/19/2013)... 19, 2013) The results of three important studies ... Neurosurgery , official journal of the Congress of ... Lippincott Williams & Wilkins , a part of ... that continuous "machine learning" using artificial neural networks (ANNs) ... with advanced brain cancers. Another study in the June ...
(Date:6/19/2013)... 2013) In early April, senior leaders from medical, ... Connecticut, to discuss one question: how can first responders ... , The preliminary results of this discussion are now ... The Hartford Consensus ," a concept paper published in ... of Trauma and Acute Care Surgery , official ...
(Date:6/19/2013)... repairing damage to the genetic material DNA become a ... those compounds are sparking optimism as potential treatments for ... BRCA, a gene that made headlines when actress Angelina ... PARP inhibitors, are the topic of the cover story ... News . C&EN is the weekly news magazine of ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on the Wisconsin Health Insurance Exchange 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... SAN FRANCISCO, Oct. 9 Genomic Health, Inc. (Nasdaq: ... demonstrating the critical role of manual microdissection to remove ... Health,s Onco type DX is the only commercially ... review by a board certified surgical pathologist with breast ...
... and LAKE FOREST, Calif., Oct. 9 Kimberly-Clark Corporation ... IFLO ), a leading healthcare company that develops and ... products for post-surgical pain relief and surgical site care, ... acquired in a cash tender offer for approximately $324 ...
... CEO Harrison Calls for Reform that Eliminates Wasteful Government ... 9 Doug Harrison, CEO and Founder of The SCOOTER ... of Health and Human Services (HHS) Inspector General,s report was ... costs of providing medical equipment to Medicare beneficiaries. , In ...
... of Ford Motor Company and the United Auto Workers are ... - they,re also coming together to support the March of ... start in life. , (Photo: http://www.newscom.com/cgi-bin/prnh/20091009/AQ90045 ) ... Dimes honored special volunteers and announced the first-ever March for ...
... ... employment law compliance obligations can now download a free 75-minute audio briefing entitled Employment ... discussion featuring five employment law attorneys with the Employers Counsel Network. , ... Nashville, TN (PRWEB) October 9, ...
... ... Physical Therapist has received a home exercise program, or HEP, that consisted of 2 to 3 ... FIZIO is a new online service that is set on changing this practice by giving health ... ...
Cached Medicine News:Health News:Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients 2Health News:Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients 3Health News:Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients 4Health News:Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients 5Health News:Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation 2Health News:Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation 3Health News:Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation 4Health News:Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation 5Health News:Kimberly-Clark Announces Definitive Agreement to Acquire I-Flow Corporation 6Health News:SCOOTER Store CEO Outraged: Flawed Data Used by Fox News Channel to Wrongly Chastise Medical Suppliers 2Health News:Ford and Labor Leaders Join Forces with March of Dimes 2Health News:New Audio Briefing Explains Obama Administration's Workplace Law Priorities 2Health News:New Audio Briefing Explains Obama Administration's Workplace Law Priorities 3Health News:New Online Service Uses Video Instruction to Simplify Physical Therapy Exercises 2Health News:New Online Service Uses Video Instruction to Simplify Physical Therapy Exercises 3Health News:New Online Service Uses Video Instruction to Simplify Physical Therapy Exercises 4
... more efficient way to control thermoregulation. ... operated patient warming system, provides hospitals, ... a compact and better way to ... process. Its unique design combines functionality ...
... WarmAir® system from CSZ safely provides effective ... of the unique patented design of our ... lower velocity blower which supplies gently moving, ... that may spread contaminants to your patient ...
Since 1964, in its plants of Sesto Fiorentino, Sbisà produces a wide and qualified range of instruments for ophthalmology and optometry....
Inquire...
Medicine Products: